Predictors of persistent fever among patients with suspected infective endocarditis: think outside the box ✅ Just Accepted 🔗 bit.ly/3Z9OEgl

Is Antibiotic De-Escalation Safe and Beneficial to Patients with Sepsis? ✅ Just Accepted 🔗 bit.ly/4f3oulF

🆕💫 Systematic review JAC-AMR Antibiotic duration for common bacterial infections Out of 315 studies, 85% concluded equivalence or non-inferiority of shorter courses Non-inferiority was the most commonly adopted design Brad Spellberg #idxposts academic.oup.com/jacamr/article…

Get ready for APCCMI 2025 The largest ID and microbiology conference in Asia Submit your abstract Register Book your flight and hotel See you in the land of smiles in November

【Nature of febrile episodes in neutropenic patients】 Important to understand the source of infections (clinical or microbiological) can only be identified in nearly half of neutropenic patients Level: Standard Importance: ★★★ #IDMedEd #IDFellow #TxID #CancerID

Join us as we crack the case on managing MDR Gram-negative bacterial infections! We’ll track the epidemiology, uncover lab clues, optimise our antibiotic arsenal with PKPD, and explore treatment strategies, IPC, and upcoming trials 🔬💥 #MDRGNB #AMR #PKPD

I still see the ESR/CRP zombies everywhere! Stop the zombie madness!

🆕💫Systematic review and meta-analysis 33 studies, including 6 RCTs and 27 observational Impact of antibiotic duration in management of diabetic foot osteomyelitis. Duration: ≤6 weeks Vs >6 weeks DFO is heterogeneous disease imho! #IDXposts sciencedirect.com/science/articl…

💊Antibiotics or not? Can procalcitonin guide therapy in AECOPD patients? 😷 🏥 Check out Dr. Chang’s latest highlight on MAMSIG 🧠💊 📖 Jom baca & level up your AMR game! 🔍🔥 #COPD #Procalcitonin #Antibiotics #MAMSIG #MedTwitter antibiotic-ninja.com/paper-highlight

We love what we do. But yes, we’d also like to get paid. ID is a cognitive, consult-heavy specialty -- and often a “loss leader” in a fee-for-service world. A look at how the money actually flows (or doesn’t), Part 1. h/t ron nahass Brad Spellberg 👇 blogs.jwatch.org/hiv-id-observa…

Prevalence, progression, and treatment of asymptomatic tuberculosis: a prospective cohort study in Lanxi County, Zhejiang Province, China ✅ Just Accepted bit.ly/4jNJSOR

Nothing is better than seeing this study published just in time for ID Pharmacists Day! 🥳 #IDXposts

Excellent correspondence Aurélien Dinh Brad Spellberg The Lancet Infectious Diseases The authors suggest that traditional 6–12 months duration of antifungal treatment in pjis caused by Candida spp must be revisited in light of the most comprehensive data currently available thelancet.com/journals/lanin…

Selective digestive tract decontamination in ICUs: Life saver or recipe for disaster? By Joshua Davis and Allen Cheng cmi-comms.com/article/S2950-…

Very interesting research on personalized treatment of invasive candidal infections was published in Critical Care doi.org/10.1186/s13054…

What’s the optimal cefazolin dose for MSSA CNS infections? New PK/PD data says: it’s not just about higher doses—MIC matters. 2g q6h works only if MIC <=0.5 mg/L For MIC:1-2 mg/L, continuous infusion (10–12g/day) may be needed to hit PD targets. #idxposts journals.asm.org/doi/10.1128/aa…

Tigecycline in HAP: A lung PBPK model shows acidic pH boosts alveolar cell exposure 12-fold, while ELF levels stay stable. Only high-dose regimen (200 mg LD + 100 mg q12h) hits PTA targets for MIC >2 mg/L. Tailored dosing may be key for resistant pathogens journals.asm.org/doi/10.1128/aa…

Comparative effectiveness of azithromycin versus doxycycline in hospitalized patients with community acquired pneumonia treated with beta-lactams: A multicenter matched cohort study ✅ Just Accepted ✍️ Aysun Tekin Ognjen Gajic doi.org/10.1093/cid/ci…

🆕 Oral vs IV antibiotics 🆕 Oral #Antibiotics are more cost-effective and may be safer than IV antibiotics for most infections in stable adults TI Therapeutics Letter 155: 👉 ti.ubc.ca/letter155 TI Best Evidence webinar: 👉 ti.ubc.ca//antibiotics-w… (free registration)

Very excited to work with Asian ADVANCE-ID network to plan clinical trials of our novel metallo-beta-lactamase (MBL) inhibitor, MET-X. Antimicrobials targeting MBL mechanism of Gram negative bacterial resistance to antibiotics is key gap in pipeline. David Paterson INFEX Therapeutics